oxantel

Small moleculeexperimental

Oxantel is an anthelmintic. It has typically been used in human and animal medicine as a treatment for intestinal worms. It has also been shown to inhibit fumarate reductase in some pathogenic bacteria. — Wikipedia

Clinical trial activity

4 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
2

Earliest trial started Dec 1, 2010 (NCT01327469)

Timeline

2020s

  1. Jan 1, 2024

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2025

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN1CCCN=C1/C=C/c1cccc(O)c1
Mol. weight
216.28 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1,4,5,6-tetrahydro-2-(3-hydroxy styryl)-1-methylpyrimidine
  • cp 14,445
  • cp-14,445
  • oxantel
  • oxantel
  • oxantel
  • oxantel
  • oxantel
  • oxantel
  • oxantel monohydrochloride, (e)-isomer
  • oxantel tartrate
  • oxantel tartrate (1:1), (r-(r*,r*))-isomer

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06720259Phase 2Feb 28, 2025University of Basel
NCT06606860Phase 1Nov 30, 2024Drugs for Neglected Diseases Initiative, Ifakara Health Institute, University of Basel
NCT03278431Phase 4Sep 27, 2017University of Basel
NCT01327469Phase 4Dec 1, 2010Ghent University, VLIR Institutional University Collaboration Programme
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of BaselAcademic/Hospital3332017
Drugs for Neglected Diseases InitiativeAcademic/Hospital1012024
Ghent UniversityAcademic/Hospital1112010
Ifakara Health InstituteAcademic/Hospital1012024
VLIR Institutional University Collaboration ProgrammeAcademic/Hospital1012010
5 organizations
Page 1 / 1